CHA ÀÇ°úÇдëÇб³ Â÷º´¿ø professor

±³¼ö´Ô»çÁø
  • ¹®¿ëÈ­
  • Ç÷¾×Á¾¾ç³»°úÀå
  • ¼Ò ¼Ó: ºÐ´çÂ÷º´¿ø
  • Àü¹®ºÐ¾ß : À¯¹æ¾Ï, ºÎÀξÏ, Àü¸³¼±¾Ï
  • Á÷ À§: ±³¼ö(Ç÷¾×Á¾¾ç³»°úÀå)
  • ¸Þ ÀÏ: ºñ°ø°³
  • Àü È­: 1577-4488
  • ÆÑ ½º:
  • ÁÖ ¼Ò: °æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßžµ¿ 351¹øÁö
  • ȨÆäÀÌÁö:
  • ·Î±×ÀÎ

ÅǸ޴º

ÁÖ¿ä¹ßÇ¥³í¹®

ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£ ±¸ºÐ Á¦¸ñ
223 (±¹¿Ü)SCI MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis
222 (±¹³»)SCI Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial.
221 (±¹¿Ü)SCI Predictive Nomogram for Recurrence of Stage I Colorectal Cancer After Curative Resection
220 (±¹¿Ü)SCIE Organizing pneumonia resembling disease progression in a non-small-cell lung cancer patient receiving ceritinib
219 (±¹³»)SCI Efficacy and Safety of a New 10% Intravenous Immunoglobulin Product in Patients with Primary Immune Thrombocytopenia (ITP)
218 (±¹¿Ü)SCIE A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer
217 (±¹¿Ü)SCI A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTKorea
216 (±¹¿Ü)±âŸ High cripto-1 and Low miR-205 Expression Levels as Prognostic Markers in Early Stage Non-Small Cell Lung Cancer
215 (±¹³»)SCOPUS A Case of Management for Advanced Hepatocellular Carcinoma with Extrahepatic Metastasis by Autologous Natural Killer Cells Combined with Immune Checkpoint Inhibitor
214 (±¹¿Ü)SCIE Incidence of venous thromboembolism in Korea from 2009 to 2013
ÀÌÀüÆäÀÌÁö À̵¿ 1 2 3 4 5 6 7 8 9 10 ´ÙÀ½ÆäÀÌÁö À̵¿
Copyright ¨Ï chamc, All rights reserved.

ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à

  • °­³²Â÷º´¿ø
  • ºÐ´çÂ÷º´¿ø
  • ºÐ´çÂ÷¿©¼ºº´¿ø
  • ±¸¹ÌÂ÷º´¿ø
  • ¿©¼ºÀÇÇבּ¸¼Ò
  • Â÷¿ò

ÀüÈ­¹®ÀÇ

  • °­³²Â÷º´¿ø 02.3468.3000
  • ºÐ´çÂ÷º´¿ø 031.780.5000
  • Â÷¿ò 02.3015.5300
  • ±¸¹ÌÂ÷º´¿ø 054.450.9700
  • ´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
  • °­³²°ÇÁø¼¾ÅÍ 02.2191.3900
  • ºÐ´çÁ¾ÇÕ°Ç°­ÁõÁø¼¾ÅÍ 031.780.5940
  • ½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
  • ±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
  • ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729